ZETONNA
LOE Approachingciclesonide
NDANASALAEROSOL, METERED
Approved
Jan 2012
Lifecycle
LOE Approaching
Competitive Pressure
15/100
Clinical Trials
20
Data completeness
5/8 — Partial
ZETONNA (ciclesonide) is pro-drug that is enzymatically hydrolyzed to a pharmacologically active metabolite, c21-desisobutyryl-ciclesonide (des-ciclesonide or rm1) following intranasal application. First approved in 2012.
Drug data last refreshed 2d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ZETONNA is a nasal metered aerosol containing ciclesonide, a pro-drug intranasal corticosteroid approved in 2012. It treats asthma, allergic rhinitis, COPD, and COVID-19 through enzymatic hydrolysis to its active metabolite des-ciclesonide, which has 120-fold higher glucocorticoid receptor affinity than the parent compound. The drug reduces allergic inflammation by suppressing multiple immune cell types and mediators including mast cells, eosinophils, and pro-inflammatory cytokines.
$0.323MPart D
LOE ApproachingDeclining
1.7 years to LOEProduct approaching loss of exclusivity with minimal Part D penetration; brand team faces significant portfolio wind-down planning.
Mechanism of Action
pro-drug that is enzymatically hydrolyzed to a pharmacologically active metabolite, C21-desisobutyryl-ciclesonide (des-ciclesonide or RM1) following intranasal application. Des-ciclesonide has anti-inflammatory activity with affinity for the glucocorticoid receptor that is 120-times higher than the…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
Inhaled Ciclesonide Study in Preterm Infants
Started Sep 2025
30 enrolled
Bronchopulmonary Dysplasia
Efficacy and Safety of Ciclesonide Nasal Spray in Participants With Seasonal Allergic Rhinitis (SAR) in Russia
Started Aug 2014
80 enrolled
Seasonal Allergic Rhinitis
Effect of High Dose Ciclesonide on Asthma Control
Started Nov 2011
520 enrolled
Bronchial Asthma
Efficacy, Safety & Tolerability of Ciclesonide 200mcg Spray 4 Weeks Treatment for Intermittent & Persistent Rhinitis
Started Aug 2011
1,630 enrolled
Perennial RhinitisSeasonal Rhinitis
Observational Study on Efficacy of Alvesco(Ciclesonide) in Asthma Children and Adolescent in Real Practice
Started Jul 2010
274 enrolled
Asthma
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.